ESMIT Live Webinar series
Easily accessible from the comfort of your home FOR FREE – Get the best ESMIT education without travelling!
Live webinars are condensed pieces of live, high-quality education which include theoretical presentations, case-based teachings, and a lot of interaction between our facilitators and our participants.
Through this series of live webinars, experts in the field of nuclear medicine will share their knowledge about various topics in an interactive online setting accessible from all over the world.
- All webinars are written and facilitated in English.
- Webinars will be held at 13:30 pm CE(S)T on Zoom Webinar and the webinars have an average duration of 60 minutes.
- After the live event has taken place, the recording will be accessible on our eLearning platform. You can access the eLearning materials by logging in with your myEANM account.
- Please note that the ESMIT Live Webinar Series is not CME accredited.
Go to eLearning platform Go to Registration
Upcoming ESMIT Live Webinars in 2023
Save the dates! We are looking forward to seeing you at the ESMIT Live Webinars in 2023:
| Clinical NM | FAPI: Focus on Inflammatory and Systemic Diseases | Live Webinar | February 3, 2023 |
| Clinical NM | JSNM: Non-ischemic Heart Disease | Live Webinar | February 17, 2023 |
| AI & Quant. | Low Dose Imaging | Recorded Webinar | February 24, 2023 |
| Theranostics | FAPI: an Update in Oncology | Live Webinar | March 3, 2023 |
| Clinical NM | Combination Therapies: Preclinical and Clinical Perspectives | Recorded Webinar | March 10, 2023 |
| AI & Quant. | How to Value Artificial Intelligence in NM | Live Webinar | March 24, 2023 |
| AI & Quant. | Dosimetry Across the Water | Live Webinar | April 14, 2023 |
| Clinical NM | Nuclear Medicine and Pregnancy | Live Webinar | April 21, 2023 |
| Clinical NM | Focus on Imaging of Parathyroid Disease | Live Webinar | May 5, 2023 |
| Clinical NM | Immuno-PET | Live Webinar | May 12, 2023 |
| Clinical NM | How to Semi-Quantify 123I-Ioflupane | Live Webinar | June 2, 2023 |
| Clinical NM | Bone Metastases: Response Assessment | Live Webinar | June 23, 2023 |
| Radiation Protection | Emerging Challenges in the Implementation of Alpha Therapies | Recorded Webinar | June 30, 2023 |
| Theranostics | Focus on Radioembolization | Live Webinar | September 29, 2023 |
| Tech | Part 1: Dosimetry in Radionuclide Therapy Planning: Primary and Metastatic Liver Tumours | Live Webinar | October 6, 2023 POSTPONED to November 3, 2023 |
| Clinical NM | Bone Densitometry in 2023: Drivers, Opportunities, Challenges | Live Webinar | October 13, 2023 |
| Tech | Dosimetry in Radionuclide Therapy Planning: Primary and Metastatic Liver Tumours and Neuroendocrine Tumours | Live Webinar | November 3, 2023 |
| Theranostics | Highlights from ESMO: What’s New for Nuclear Medicine | Live Webinar | November 24, 2023 |
| Clinical NM | Evidence-based Guidelines on Imaging in Vascular Graft Infection | Live Webinar | December 15, 2023 |
Upcoming ESMIT Live Webinars in 2024
Save the dates! We are looking forward to seeing you at the ESMIT Live Webinars in 2024:
| Clinical NM | Diagnostic and Therapy of Medullary Thyroid Cancer | Live Webinar | February 2, 2024 |
| Clinical NM | Cardiac Hybrid Imaging | Live Webinar | February 9, 2024 |
| AI & Quant. | Full Quantification for Brain Imaging | Live Webinar | March 1, 2024 |
| Radiopharma-ceuticals | Basic GMP and the Challenges of Annex 1: Manufacture of Sterile Products | Live Webinar | April 12, 2024 |
| Theranostics | Exploiting Radiobiological Effects of Targeted Radionuclide Therapy | Live Webinar | April 19, 2024 |
| Instrumentation, Technology, Science |
CT Optimization in Hybrid Imaging | Live Webinar | June 7, 2024 |
| Clinical NM | Cardiovascular PET-CT and PET-MR Imaging | Live Webinar | June 14, 2024 |
| Clinical NM | Guidelines for the Use of FDG-PET/CT in Infection and Inflammation 2.0 | Live Webinar | July 5, 2024 |
| Clinical NM | FDG-PET/CT in Breast Cancer | Live Webinar | September 6, 2024 |
| Clinical NM | Paediatric Nuclear Medicine in Nephro-Urology | Live Webinar | September 20, 2024 |
| AI & Quant. | Artificial Intelligence in Dosimetry | Live Webinar | November 8, 2024 |
| Theranostics | Challenges of Zr89 Imaging | Live Webinar | November 22, 2024 |
| Clinical NM | Treatment of Metastatic Bone Pain using Bone-seeking Agents | Live Webinar | December 6, 2024 |
Click here to register for the ESMIT Live Webinars through the ESMIT registration tool connecting your eLearning account directly to your myEANM account!
You can also access the course store by logging into your myEANM account, clicking “eLearning platform” and then choosing ‘Register Now!’ in the horizontal navigation.
Upcoming ESMIT Live Webinars
December 15, 2023 – Evidence-based Guidelines on Imaging in Vascular Graft Infection
December 15, 2023 – 13:30 CET
| Speakers: | Nabil Chakfé |
 Roberto Iezzi |
 Chiara Lauri |
 Giorgio Treglia |
| Moderator: | Olivier Gheysens |
Content:
Vascular graft infection (VGI) is a serious complication of vascular surgery associated with a poor prognosis and high mortality rate. The diagnosis of VGI is challenging, highly dependent on imaging findings and requires a multimodality and multidisciplinary approach. Several radiological and NM modalities are available, each one with its pros and cons. This webinar will provide evidence-based answers to several practical questions raised by clinicians and surgeons when they approach imaging in order to plan the most appropriate radiological and/or NM examination for each patient with suspected VGI.
Learning Objectives:
Faculty:
Nabil Chakfé: University hospital of Strasbourg, Department of vascular surgery and kidney transplantation – Strasbourg, France
Roberto Iezzi: Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Dipartimento di diagnostica per immagini, radioterapia oncologica ed ematologia – Rome, Italy
Chiara Lauri: S. Andrea Hospital, Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, “Sapienza” University of Rome – Rome, Italy
Giorgio Treglia: Ente Ospedaliero Cantonale, Imaging Institute of Southern Switzerland, Clinic of Nuclear Medicine – Bellinzona, Switzerland
Olivier Gheysens
February 2, 2024 – Diagnostic and Therapy of Medullary Thyroid Cancer
February 2, 2024 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
February 9 – Cardiac Hybrid Imaging
February 9, 2024 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
March 1, 2024 – Full Quantification for Brain Imaging
March 1, 2024 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
April 12, 2024 – Basic GMP and the Challenges of Annex 1: Manufacture of Sterile Products
April 12, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
April 19, 2024 – Exploiting Radiobiological Effects of Targeted Radionuclide Therapy
April 19, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
June 7, 2024 – CT Optimization in Hybrid Imaging
June 7, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
June 14 – Cardiovascular PET-CT and PET-MR Imaging
June 14, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
July 5 – Guidelines for the Use of FDG PET/CT in Infection and Inflammation 2.0
July 5, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
September 6 – FDG-PET/CT in Breast Cancer
September 6, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
September 20 – Paediatric Nuclear Medicine in Nephro-Urology
September 20, 2024 – 13:30 CEST
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
November 8 – Artificial Intelligence in Dosimetry
November 8, 2024 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
November 22, 2024 – Challenges of Zr89 Imaging
November 22, 2023 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
December 6, 2024 – Treatment of Metastatic Bone Pain Using Bone-Seeking Agents (MSK)
December 6, 2024 – 13:30 CET
| Speakers: | ||
| Moderator: |
Content:
More info is coming soon.
Learning Objectives:
Faculty:
More info is coming soon.
Past ESMIT 2023 Live Webinars
February 3, 2023 – FAPI: Focus on Inflammatory and Systemic Diseases
February 3, 2023 – 13:30 CET
| Speakers: |
 David Morland |
 Anna Sviridenko |
| Moderator: |
 Soren Hess |
Content:
68Ga-FAPI has been developed as a tumour-targeting agent as fibroblast activation protein is over-expressed in cancer-associated fibroblasts. FAP over-expression has, however, been also noted in osteoarthritis and some other inflammatory diseases such as Ig-G4 related disease, pulmonary fibrosis, retroperitoneal fibrosis and, more recently, in long COVID. This webinar aims at detailing the ongoing studies and the perspectives offered by 68Ga-FAPI in these new indications, insisting in particular on its added value compared to the already existing imagery and tracers.
Learning Objectives:
Faculty:
David Morland: MCU-PH – Unité de Médecine Nucléaire, Institut Godinot, Reims – Reims, France
Anna Sviridenko: Medical University Innsbruck, Nuclear Medicine Department – Innsbruck, Austria
Soren Hess: Chief of Radiology and Nuclear Medicine, Head of Research, Associate Professor, Department of Radiology and Nuclear Medicine, University Hospital of Southern Denmark – Hospital of Southwest Jutland, Esbjerg, Denmark – Esbjerg, Denmark
February 17, 2023 – JSNM: Non-ischemic Heart Disease
February 17, 2023 – 13:30 CET
| Speakers: |
 Yasuyo Taniguchi |
 Federico Caobelli |
 Kenichi Nakajima |
 Carmela Nappi |
| Moderator: |
 Fabien Hyafil |
Content:
This webinar will focus on the use of nuclear medicine procedures in the area of non-ischemic cardiomyopathies.
This group of diseases is the cause of about one in three heart failures and the most common reason for heart transplantation. Non-ischemic cardiomyopathies are structural and functional dysfunctions of the myocardium in the absence of causative coronary artery disease, hypertension, valvular disease, or congenital heart disease. In this group of heart diseases, nuclear cardiology imaging can play a central role. This webinar will focus on the following forms of non-ischemic cardiomyopathies: cardiac amyloidosis, triglyceride deposit cardiomyovasculopathy (TGCV), Fabry disease, and myocarditis.
The goal is to learn about the different forms of non-ischemic cardiomyopathies and the specific use of nuclear medicine techniques. The contents will be explained by means of specific case examples. Pitfalls in imaging will also be explained. Audience members from the fields of nuclear medicine, radiology, cardiology and internal medicine in general will be addressed. The program is designed to interest medical students, residents, specialists, as well as technicians.
Learning Objectives:
After this webinar, participants will know how:
- To learn about the different forms of non-ischemic cardiomyopathies.
- To understand the useful application of nuclear medical imaging.
- To gain insights into diagnostics on the basis of specific case studies.
- To gain an insight into possible future developments in the field.
Faculty:
Yasuyo Taniguchi: Division of Cardiovascular Medicine, Hyogo Prefectural Himeji Cardiovascular Center – Hyogo, Japan
Federico Caobelli: University Clinic of Nuclear Medicine, Inselspital Bern and University of Bern – Bern, Switzerland
Kenichi Nakajima: Department of Functional Imaging and Artificial Intelligence, Kanazawa Univeristy – Kanazawa, Japan
Carmela Nappi: Department of Advanced Biomedical Sciences, University Federico II – Naples, Italy
Fabien Hyafil: DMU IMAGINA, Hôpital Européen Georges-Pompidou, Nuclear Medicine Department – Paris, France
February 24, 2023 – Low Dose Imaging (Pre-recorded)
February 24, 2023 – 09:00 CET
| Speakers: |
 Sigrid Leide-Svegborn |
 John Dickson |
 Florence Muller |
| Moderator: |
 Anne Larsson Strömvall |
Content:
In nuclear medicine, the imaging procedures involve a combination of the selection of a radiopharmaceutical, the injection of a certain dose of radioactivity, SPECT or PET imaging during a certain acquisition time, and the selection of a collimator in the case of SPECT. The goal is to optimise each of these parameters to obtain an image quality that allows the nuclear medicine physicians to answer the clinical questions. The tendency is to moderate the injected activity and/or reduce acquisition time to minimize potential radiation hazards and increase patient comfort. The difficulty is that better image quality usually is associated with a higher dose of radioactivity and/or longer acquisition times, which are proportional to the number of detected events and hence the noise characteristics of SPECT and PET images. However, the rapid technological evolution of scanners, hardware as well as software for image acquisition and reconstruction, has allowed a dramatic improvement of efficiency and image quality, resulting in progressive reduction of radiation doses to the patient. This is of special importance when performing nuclear medicine procedures on children and pregnant patients, which will be highlighted in this webinar. We will also present the major evolutions in nuclear medicine that have an impact on radiation dose reduction. For example, with the introduction of total body PET scanners the injected activity and acquisition time can be reduced, and ultra-low-dose imaging become feasible. During recent years, also deep learning algorithms have been deployed for various tasks, exhibiting superior performance over traditional strategies. These algorithms are capable of predicting full-dose images from low-dose images which can have a high impact on future dose reduction.
Learning Objectives:
Faculty:
Sigrid Leide-Svegborn: Skåne University Hospital, Lund University, Radiation physics –Malmö, Sweden
John Dickson: University College London Hospitals, Institute of Nuclear Medicine – London, United Kingdom
Florence Muller: Ghent University, Department of Electronics and Information Systems, Medical Image and Signal Processing – Ghent, Belgium
Anne Larsson Strömvall: Umeå University, Radiation Physics Dept – Umeå, Sweden,
March 3, 2023 – FAPI: an Update in Oncology
March 3, 2023 – 13:30 CET
| Speakers: |
 Katharina Dendl |
 Kumar Kallur |
| Moderators: |
 Vikram Lele |
 Gopinath Gnanasegaran |
Content:
There is evolving evidence in the development and use of quinoline-based PET tracer fibroblast-activation-protein inhibitors (FAPIs) in oncology. Several promising and fascinating preclinical and clinical results have been published. The faculty will review and discuss current evidence, clinical applications, and future perspectives of FAPI PET-CT in oncology.
Learning Objectives:
After this webinar, participants will know about:
- Current evidence and clinical applications of FAPI PET-CT in oncology.
- Advantages, limitations, and challenges in diagnostic and therapeutic settings.
Faculty:
Katharina Dendl: Department of Nuclear Medicine, Medical Faculty of Heinrich Heine University, University Hospital Düsseldorf, Düsseldorf, Germany. Department of Nuclear Medicine, University Hospital Heidelberg – Heidelberg, Germany
Kumar G Kallur: Director of Molecular Imaging and Nuclear Medicine at HCG Cancer Centre – Bangalore, India
Vikram Lele: Director of the Jaslok Hospital & Research Center’s Department of Nuclear Medicine and PET-CT – Mumbai, India
Gopinath Gnanasegaran: Consultant In Nuclear Medicine, Royal Free London NHS Foundation Trust, Hon Consultant in Nuclear Medicine, University College London Hospitals NHS Foundation Trust – London, UK
March 10, 2023 – Combination Therapies: Preclinical and Clinical Perspectives (Pre-recorded)
March 10, 2023 – 09:00 CET
| Speakers: |
 Angela Lamarca |
 Jean Pierre Pouget |
 Clément Morgat |
 Mike Sathekge |
| Moderators: |
 Chiara Maria Grana |
Gopinath Gnanasegaran |
Content:
Modern nuclear medicine is facing the challenge to apply minimally invasive treatment strategies that suit the needs of the individual patient: it is called precision medicine.
Its aim is to improve patient care by stratifying patients into sub-groups that can be managed with tailored treatment plans.
The success of nuclear medicine depends on three important points:
1) clinical implementation of available nuclear medicine technologies,
2) development of innovative nuclear medicine technologies
3) translating these new developments from the preclinical setting into the clinic.
In Nuclear Medicine we have the possibility to know the molecular characteristics of the disease by functional imaging, in order to propose a tailored treatment, that can be improved by the association of a radiopharmaceutical and a different drug, as immunotherapy, chemotherapy, target therapy.
Learning Objectives:
Faculty:
Angela Lamarca: Department of Medical Oncology, Oncohealth Institute, Fundación Jimenez Diaz University Hospital, Madrid, Spain Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; University of Manchester, Manchester, United Kingdom – Madrid, Spain and Manchester, United Kingdom
Jean Pierre Pouget: Institute for Neurosciences of Montpellier – Montpellier France
Clément Morgat: University Hospital of Bordeaux – Nuclear Medicine Department and University of Bordeaux – Multimodal Imaging Team – Bordeaux, France
Mike Sathekge: University of Pretoria & Steve Biko Academic Hospital – Pretoria, South Africa
Chiara Maria Grana: IRCCS IEO European Institute of Oncology – Milan, Italy
Gopinath Gnanasegaran: Royal Free London NHS Foundation Trust – Dept of Nuclear Medicine – London, United Kingdom
March 24, 2023 – How to Value Artificial Intelligence in Nuclear Medicine
March 24, 2023 – 13:30 CET
| Speakers: |
 Mathieu Hatt |
 Margarita Kirienko |
| Moderator: |
John Dickson |
Content:
Artificial intelligence (AI) is making an impact in many areas of medicine, and has seen rapid steps in techniques developed in radiology. Similar steps are being worked on in Nuclear Medicine, but it is not always clear to the nuclear medicine professional how and where AI will make an impact, and how it could be deployed in our clinics. In this 1-hour webinar, we will investigate the potential AI has in improving our working practices, and understand how it my work in our nuclear medicine clinics.
Learning Objectives:
Faculty:
Mathieu Hatt: Director of research at the French national Institute for health and medical research (INSERM). Laboratory of medical information processing (LaTIM), INSERM and University of Brest UMR 1101 – Brest, France
Margarita Kirienko: IRCCS Istituto Nazionale dei Tumori di Milano, Nuclear Medicine – Milan, Italy
John Dickson: University College London Hospitals, Institute of Nuclear Medicine – London, United Kingdom
April 14, 2023 – Dosimetry Across the Water
April 14, 2023 – 13:30 CEST
| Speakers: |
 Yuni Dewaraja |
 Price Jackson |
 Jonathan Gear |
| Moderator: |
 Johannes Tran-Gia |
Content:
The treatment of cancer has developed rapidly in recent years. Among the increasingly applied forms of therapy are radiopharmaceutical therapies using radiolabelled carrier molecules specifically targeted to binding sites overexpressed by target cells. Partly due to the very heterogeneous regulatory framework for radiation protection worldwide, the extent of its clinical application, and thus its methodological framework, is also very country-dependent. To get the best from all worlds, invited speakers from the US, Europe and Australia will, in this course, highlight the best efforts and achievements that have been made in the field of internal dosimetry over the last years in their respective continent.
Learning Objectives:
Faculty:
Yuni Dewaraja: University of Michigan – Michigan, USA
Price Jackson: Peter MacCallum Cancer Centre – Melbourne, Australia
Jonathan Gear: Royal Marsden NHSFT – London, UK
Johannes Tran-Gia: Klinik und Poliklinik für Nuklearmedizin, Uniklinikum Würzburg – Würzburg, Germany
April 21, 2023 – Nuclear Medicine and Pregnancy
April 21, 2023 – 13:30 CEST
| Speakers: |
 Sigrid Leide Svegborn |
 Fedro Peccatori |
| Moderator: |
 Jolanta Kunikowska |
Content:
This webinar aims at detailing the current radioprotection guideline for pregnant women in case of clinical indication to sentinel lymph node scintigraphy, lung perfusion/ventilation scintiscan, a special case of Low Dose PET; radiation protection during pregnancy and in case of accidental exposure, risk assessment, ethical issues, pregnancy after radionuclide therapy, how to preserve fertility, carcinoid syndrome control.
Learning Objectives:
Faculty:
Jolanta Kunikowska: Associate Professor, Department of Nuclear Medicine, Medical University of Warsaw – Warsaw, Poland
Sigrid Leide Svegborn: Associate Prof., Department of Radiation Physics, Skåne University Hospital, Malmö, and Medical radiation physics, Department of translational medicine, Lund University, Sweden – Malmö, Sweden
Fedro Peccatori: Director of the Fertility & Procreation Unit, Division of Gynecologic Oncology, European Institute of Oncology IRCCS – Milan, Italy
May 5, 2023 – Focus on Imaging of Parathyroid Disease
May 5, 2023 – 13:30 CEST
| Speakers: |
 David Taieb |
 Martin Hüllner |
 Frederic Sebag |
| Moderator: |
 Petra Petranovic Ovcaricek |
Content:
In recent years an important development in technology and molecular imaging of parathyroid disease occurred, and at this moment, SPECT and PET imaging are available. This webinar will focus on the role of SPECT tracers and PET imaging, including the role of PET/MRI in the setting of hyperparathyroidism, to understand the correct use, the advantages and disadvantages of each technique according to the recently published EANM guidelines, with the special point of view of the surgeon.
Learning Objectives:
- Know about the role of SPECT tracers and PET imaging, including the role of PET/MRI in the setting of hyperparathyroidism.
- Understand the correct use, the advantages and disadvantages of each technique according to the recently published EANM guidelines, with the special point of view of the surgeon.
Faculty:
David Taieb: Department of Nuclear Medicine, La Timone University Hospital – Marseille, France
Martin Hüllner: Deputy Head of Department, Section head PET/CT/MR imaging, Department of Nuclear Medicine, University Hospital Zurich – Zurich, Switzerland
Frederic Sebag: Head of Endocrine Surgery, AixMarseille University, La Conception University Hospital Marseille – Marseille, France
Petra Petranovic Ovcaricek: Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice – Zagreb, Croatia
May 12, 2023 – Immuno-PET
May 12, 2023 – 13:30 CEST
| Speakers: |
 Danielle Vugts |
 Caroline Rousseau |
 Stijn Muselaers |
| Moderator: |
 Clement Bailly |
Content:
Immuno Positron Emission Tomography(Immuno-PET) uses both the target-specific
monoclonal antibody (mAb) and the sensitivity of PET. Several mAbs and radionuclides are
being evaluated in developing Immuno-PET probes. There have been significant
developments in radiochemistry and conjugation strategies. Immuno-PET could be a
method of choice for imaging specific tumour markers, which might be helpful in
theragnostic applications. In this webinar, the faculty will discuss the practical aspects of
pre-clinical and clinical applications of Immuno-PET.
Learning Objectives:
- Understand developments in radiochemistry and conjugation strategies.
- Know about practical aspects of pre-clinical and clinical applications of Immuno-PET.
Faculty:
Clement Bailly: Centre Hospitalier Universitaire de Nantes – Nantes, France
Danielle Vugts: Associate Professor in PET radiopharmaceutical chemistry with a special focus on drug development at Amsterdam UMC, The Netherlands – Amsterdam, The Netherlands
Caroline Rousseau: Head Master of Nuclear Medicine Unit, .C.O René Gauducheau, St. Herblain
France – St. Herblain, France
Stijn Muselaers: Radboud Universitair Medisch Centrum, Nijmegen, The Netherlands – Nijmegen, The Netherlands
June 2, 2023 – How to Semi-Quantify 123I-Ioflupane
June 2, 2023 – 13:30 CEST
| Speakers and Moderators: |
 Valtteri Kaasinen |
 Andrea Chincarini |
Content:
Clinical introduction to movement disorders with a particular focus on the situations when quantification is desirable. Brief methodological review on DAT semi-quantification methods, introduction to alternative approaches, pros and cons of advanced techniques and data quality issues.
Learning Objectives:
Faculty:
Valtteri Kaasinen: Professor of Neurology, Department of Clinical Neurosciences, Faculty of Medicine, University of Turku – Turku, Finland
Andrea Chincarini: Senior Researcher and Coordinator at the Istituto Nazionale di Fisica Nucleare (INFN) – Genova, Italy
June 23, 2023 – Bone Metastases: Response Assessment
June 23, 2023 – 13:30 CEST
| Speakers: |
 Elizabeth Triumbari |
 Maxime Lelièvre |
| Moderator: |
 David Morland |
Content:
Bone metastases are common and cause significant morbidity. With the advent of new therapies, particularly in breast and prostate cancer, a reliable evaluation of the metastatic response is more than ever essential for the identification of non-responder patients. Nuclear medicine has a large choice of tracers, allowing either direct analysis of metastatic tumour cells or indirect analysis of the bone response to the aggression caused by metastases. The interpretation and limitations of these examinations must be known. Immunotherapy, with the appearance of the pseudoprogression phenomenon, has also modified the way of approaching the therapeutic response, including the interpretation of the response of bone metastases.
Learning Objectives:
- Summarize the physiopathology of bone metastases formation and response under treatment.
- Describe the most used radiopharmaceuticals (bone-seeking agents vs tumour cell radiotracers).
- Describe the main pitfalls, including pseudoprogression and flare-up phenomenon.
Faculty:
David Morland: Institut Godinot and Reims Champagne-Ardenne University (CReSTIC EA 3804) – Reims, France
Elizabeth Triumbari: Department of Biomedicine and Prevention, University Tor Vergata – Rome, Italy
Maxime Lelièvre: Institut Godinot Nuclear Medicine Department – Reims, France
June 30, 2023 – Emerging Challenges in the Clinical Implementation of Alpha Therapies (Pre-recorded)
June 30, 2023 – 09:00 CEST
| Speakers: |
 Mike Sathekge |
 Mickaël Bourgeois |
 Allison Craig |
 Pablo M. Gabiña |
Content:
In recent years, radiopharmaceutical therapy using alpha-emitting radionuclides has emerged as a promising strategy to treat cancer, showing remarkable therapeutic efficacies in clinical trials. Despite its favourable cell-killing properties, the development of these therapies has been hindered by the limited availability of the radionuclides, the challenging radiochemistry, and the difficulties in quantifying the uptake in tumours and organs at risk. Following the success of the ESMIT Live Webinar on ‘Alpha-Emitters: Still a Game for Scientists or Ready for the Clinical Arena?’, this new webinar will focus on providing basic guidance on the practical uses of alpha-emitters and will critically appraise the advantages and challenges if their clinical translation as compared to conventional beta-emitting therapies. The course will review and present emerging clinical applications, provide an update on the security of the supply of radionuclides to meet clinical demand, the chemistry and radiation protection challenges associated with the pharmacokinetics and potential organ toxicity, and how to use imaging and dosimetry methods to guide therapy.
Learning Objectives:
After this webinar, participants will:
- Gain insights into the status of alpha therapies, including current and emerging clinical applications.
- Understand limitations in the production of alpha emitters and its radiochemistry challenges.
- Refresh on the importance of radiation protection and its challenges for alpha emitters.
- Learn how to use imaging to quantify alpha emitters in-vivo: advantages and limitations.
- Learn the methodology to perform dosimetry calculations and its relevance in treatment optimisation.
Faculty:
Mike Sathekge: Professor and Head of Nuclear Medicine department at University of Pretoria and Steve Biko Academic Hospital – Pretoria, South Africa
Mickaël Bourgeois: Associate Professor and Radiopharmacist (PharmD) in the Nuclear Medicine Department of Nantes University Hospital and Head of the Radiopharmacy Unit at the ARRONAX cyclotron – Nantes, France
Allison Craig: Senior Nuclear Medicine Physicist at the Royal Marsden Hospital – Sutton, UK
Pablo Mínguez Gabiña: Department of Medical Physics and Radiation Protection, Gurutzeta-Cruces University Hospital/ Biocruces Bizkaia Health Research Institute, Barakaldo, Spain and Faculty of Engineering, Department of Applied Physics, Bilbao, Spain – Barakaldo, Spain
September 29, 2023 – Focus on Radioembolization
September 29, 2023 – 13:30 CEST
| Speakers: |
 Marnix Lam |
 Manuel Weber |
 Daniel Puhr-Westerheide |
| Moderator: |
 Jens Theysohn |
Content:
Radioembolization is a locoregional treatment technique for hepatic malignancies and has significantly evolved. However, there are several necessary steps toward the best possible outcome, such as patient selection, pre-treatment angiographic assessment, shunt evaluation with nuclear medicine imaging, amount of radioactivity to be delivered, treatment procedure, and post-treatment radionuclide imaging. A collaborative effort from oncologists, interventional radiologists, and the Nuclear Medicine team is vital. The webinar will review and discuss the current tracers, techniques, and other future developments related to radioembolization.
Learning Objectives:
- Understand the science, practice, and principles of radioembolization.
- Undestand current evidence and challenging scenarios in radioembolization.
- Learn about emerging applications and techniques.
Faculty:
Marnix Lam: Professor of Nuclear Medicine, Chief of Nuclear Medicine, University Medical Center Utrecht, Department of Radiology and Nuclear Medicine – Utrecht, The Netherlands
Jens Theysohn: Prof. Dr. med., University Hospital Essen, Institute of Diagnostic and Interventional Radiology and Neuroradiology – Essen, Germany
Daniel Puhr-Westerheide: Senior Physician, LMU Klinikum, Klinik und Poliklinik für Radiologie – Munich, Germany
Manuel Weber: Department of Nuclear Medicine, University Clinic Essen, Attending Physician – Essen, Germany
October 13, 2023 – Bone Densitometry in 2023: Drivers, Opportunities, Challenges
October 13, 2023 – 13:30 CEST
| Panellists: |
 Ambre Hittinger |
 Isabelle Charlot |
| Moderator: |
 David Morland |
Content:
The diagnosis of osteoporosis has traditionally been based on bone mineral density (BMD) measurement using dual-energy X-ray absorptiometry (DXA). However, most fragility fractures occur in non-osteoporotic individuals according to their BMD status. Recent insights stress the importance of other risk factors associated with bone quality, both clinical and based on imaging. For example, the trabecular bone score (TBS) has been shown to contribute independent prognostic information when added to the validated FRAX risk assessment tool. The correct implementation and interpretation are essential to solving the current under-screening and undertreatment of patients.
Bone and muscle form a single unit with shared regulation. While the epidemiology of sarcopenia has not yet been firmly established and the diagnostic techniques need further standardization, the connection with osteoporosis has been firmly established. The pathophysiology of both conditions is multifactorial, with causal factors including hormonal changes, low level of physical activity, low intake of dietary protein, and chronic inflammation. Using DXA, nuclear medicine can play an essential role in the diagnosis and management of the osteosarcopenia disease spectrum.
Learning Objectives:
- Know the state-of-the-art in diagnostic techniques and risk stratification of patients with osteoporosis.
- Recognize the intricate connection between muscle and bone, with sarcopenia as an emerging important risk factor.
Faculty:
David Morland: Institut Godinot and Reims Champagne-Ardenne University (CReSTIC EA 3804) – Reims, France
Ambre Hittinger: Medical Hospitalist Practitioner, Rheumatology Unit in Reims University Hospital – Reims, France
Isabelle Charlot: Service de Rhumatologie, Hôpital Maison Blanche, CHU de Reims – Reims, France
November 3, 2023 – Dosimetry in Radionuclide Therapy Planning: Primary and Metastatic Liver Tumours and Neuroendocrine Tumours
November 3, 2023 – 13:30 CET
| Speaker: |
 Bartolomeo Cassano |
 Jonathan Gear |
| Moderator: |
 Paolo Turco |
Content:
Neuroendocrine tumours (NETs) are rare tumours that start in neuroendocrine cells. Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy utilising a peptide radiolabelled with Lu-177 or Y-90 designed to target the somatostatin receptors overexpressed on NETs of patients presenting with well-differentiated or moderately differentiated neuroendocrine carcinomas. Meta-iodobenzylguanidine is a noradrenaline analogue and which when labelled with 131-I, is used as a radiotherapeutic metabolic agent in neuroectodermal tumours such as Neuroblastoma, the most common extracranial solid tumour of childhood.
Application of dosimetry in both these treatments has had a long and successful history with significant evidence of dos response relationships (safety and efficacy). Recent initiatives have seen multicentre randomised controlled trial utilising dosimetry in the optimisation of treatment with greatly anticipated results. This webinar provides an overview of methodologies of image and non-image-based treatment planning and verification supporting personalized dosimetry in treating NETs. Dose-response studies and international guidelines are reviewed and open issues about the quantitative accuracy discussed.
Learning Objectives:
Faculty:
Bartolomeo Cassano: Medical Physicist, IRCCS Regina Elena National Cancer Institute – Rome, Italy
Jonathan Gear: Radioisotope Physicist at The Royal Marsden NHS Foundation Trust – London, UK
Paolo Turco: Head of the Technologists Nuclear Medicine Department, University Hospital of Padova – Padua, Italy
November 24, 2023 – Highlights from ESMO: What’s New for Nuclear Medicine
November 24, 2023 – 13:30 CET
| Speakers: |
 Karolien Goffin |
 Carsten Kobe |
| Moderator: |
 Ken Herrmann |
Content:
The European Society for Medical Oncology (ESMO) is a leading professional organization for medical oncology. ESMO organizes several oncology-related programs, some focusing on Diagnostic and Therapeutic Applications of Nuclear Medicine in Oncology. ESMO regularly updates the Clinical Practice Guidelines and consensus recommendations developed by the top experts. The webinar will review and share the discussions and highlights from ESMO proceedings.
Learning Objectives:
- Emerging applications and trends in Oncology
- Clinical Trials in related to Diagnostic, and Therapeutic Applications of Nuclear Medicine in Oncology
Faculty:
Ken Herrmann: Chair of the Department of Nuclear Medicine at the Universitätsklinikum Essen and as Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at UCLA – Essen, Germany
Karolien Goffin: Nuclear Medicine & Molecular Imaging, University Hospital Leuven, KU Leuven – Leuven, Belgium
Carsten Kobe: Department for Nuclear Medicine, University Hospital of Cologne – Cologne, Germany